INTRODUCTION
Chronic myelogenous leukemia (CML) is a myeloproliferative cancer with BCR-ABL fusion genes in hematopoietic progenitor cells. Bcr-Abl selective tyrosine kinase inhibitor imatinib mesylate (Glivec or Gleevec) has substantially improved the treatment landscape for CML (Druker et al., 1996) . Nonetheless, some patients are refractory to imatinib and eventually develop imatinib resistance (Hochhaus et al., 2007) . The resistance to imatinib is related with BCR-ABL dependent mechanism via point mutations on Bcr-ABL fusion protein or independent mechanism via activation of Src family kinase (Valent, 2007; Ramirez and DiPersio, 2008) .
1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG), a naturally occurring gallotannin polyphenolic compound from Rhus chinensis Mill, showed anti-proliferative, antiangiogenic, anti-diabetic and apoptotic activities (Zhang et al., 2009) .
Also, it is of note that PGG exerts antitumor activity in various cancers such as prostate (Hu et al., 2008) , lung (Huh et al., 2005) , breast (Chen et al., 2003) , melanoma (Ho et al., 2002) , liver cancers (Oh et al., 2001 ) and sarcomas (Miyamoto et al., 1987) . Nevertheless, there are no evidences regarding the synergistic antitumor effect of PGG with imatinib so far. Thus, in the current study, the antitumor potential of PGG to induce apoptosis and enhance antitumor activity of imatinib in K562 cells and animal study using immunohistochemistry was elucidated in vitro and in vivo.
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MATERIALS AND METHODS

Isolation of PGG
PGG was isolated from the gallnut of Rhus chinensis Mill as previously described (Chai et al., 2010) . The yellowish active compound was identified as PGG by nuclear magnetic resonance (NMR) and fast atom bombardment mass spectrometry (FAB-MS) analyses. The purity of PGG was estimated to be >96% by high performance liquid chromatography (HPLC).
Cell culture
K562 (CML) cells purchased from American Type Culture Collection (ATCC) (Rockville, MD) were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% fetal bovine serum (FBS).
Cell viability assay
Cytotoxicity of PGG was determined using sodium 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT) assay. Cells (2 × 10 4 cells/100 µl/well) were seeded on 96-well microplates, treated with various concentrations of PGG (0, 10, 20, 40 µM) for 24 h and incubated with XTT labeling mixture [125 µM XTT/25 µM phenazine methosulphate (PMS)] at 37°C for 2 h. Optical density (OD) was measured using a microplate reader (Molecular Devices Co., Sunnyvale, CA) at 450 nm. 
Western blotting
Western blotting was performed as previously described (Seo et al., 2011) . Whole cell extracts were prepared using cell lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM Ethylenediaminetetraacetic acid (EDTA), 1% NP-40, 0.25% deoxycholate acid) containing protease inhibitor cocktail (Roche Applied Science, Inndianapolis, IN). Protein samples were quantified by using Bio-Rad DC protein assay kit II (Bio-Rad, Hercules, CA), separated onto 8 to 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and electrotransferred to a nitrocellulose membranes. After blocking with 5% nonfat skim milk, the blots were probed with antibodies against Poly (ADP-ribose) polymerase (PARP) (Santa Cruz Biotechnology, Santa Cruz, CA), and β-actin (Sigma, St. Louis, MO), and exposed to horseradish peroxidase (HRP)-conjugated anti-mouse or rabbit secondary antibodies. Protein expression was detected by using enhanced chemiluminescence (ECL) system (Amersham Pharmacia, Piscataway, NJ).
Mouse xenograft model
The animal studies were conducted under guidelines approved by Institutional Animal Care and use Committee, Kyung Hee University [KHUASP(SE)-11-005]. Five-week-old female athymic nude mice were purchased from Jung Ang lab animal (Seoul, Korea) and maintained under conventional conditions. K562 cells (5 × 10 6 cells) were mixed with matrigel (Becton Dickinson, 50%, in 100 µl) and Kwon et al. 553 injected subcutaneously on the right flank of the mice. After 5 days of inoculation, the mice were given intraperitonial (i.p) injection of PGG at 4 or 10 mg/kg body weight or imatinib at 25 or 50 mg/kg body weight in 50% PEG 400/50% saline (v/v) every 2 days for 18 days. Control mice were administered the solvent vehicle. Tumor volume was measured every other day with caliper and calculated according to the formula; V = 0.52a 2 b, where a is the smallest superficial diameter and b is the largest superficial diameter.
Immunohistochemistry
The animals were sacrificed 18 days after inoculation of K562 cells. Tumors were immediately removed, fixed in 4% PFA, paraffinembedded, and sectioned at 4 µm. Antigen retrieval was performed after dewaxing and dehydration of the tissue sections by microwaving them for 10 min in 10 mM citrate buffer. Sections were cooled to room temperature, treated with 3% hydrogen peroxide in methanol for 10 min, and blocked with 6% horse serum for 40 min at room temperature. Sections were then incubated with the primary antibodies for Ki-67 (Lab Vision Corporation, Fremont, CA), CD34 (Abcam, Boston, MA), TUNEL (Calbiochem, Darmstadt, Germany), and DAXX (Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C overnight. Sections were washed in PBS and incubated with secondary antibody (biotinylated goat anti-rabbit (Vector laboratories, Burlingame, CA) or biotinylated rabbit anti-rat IgG (Abcam, Boston, MA) for 30 min. The antibodies were detected with the vector avidin biotin complex (ABC)/HRP kit (Vector Laboratories, Burlingame, CA) and color-developed with 3,3'-diaminobenzidine tetrahydrochloride (DAB·4HCl).
Statistical analysis
Data were presented as means ± standard deviation (SD) of a minimum of 3 or more replicates. The statistically significant differences between control and PGG-treated groups were calculated by Student's t-test using Sigmaplot software (Systat Software Inc., San Jose, CA).
RESULTS
PGG synergistically enhances the antitumor activity of imatinib in K562 cells
Imatinib is an anti-cancer drug currently used to treat chronic myeloid leukaemia (CML) patients by targeting Bcr-Abl activity (Druker and Lydon, 2000) . We tested the possibility that PGG could stimulate apoptosis in CML cells induced by Imatinib. Cells were treated with various concentrations of PGG (0, 10, 20 or 40 µM) in the absence or presence of imatinib (0.25 µM) for 24 h. The cell viability was significantly decreased in combination of PGG with imatinib in a dose-dependent manner compared with the cells treated with either drug alone ( Figure  1A ). PGG obviously revealed the synergistic effect on imatinib-induced cell death with combination interval (CI) value = 0.180, 0.005 and 0.001 at 10, 20 and 40 µM, respectively ( Figure 1B ). In addition, PGG treatment further increased PARP cleavage by combination with imatinib ( Figure 1C) . These results suggest the potential of PGG for combinational therapy suggest the potential of PGG for combinational therapy with imatinib for CML chemotherapy. Consistent with PARP cleavage, treatment of PGG (20 µM) with imatinib (0.25 µM) increased the accumulation of the sub-G1 apoptotic portion by 5.15 ± 0.34 compared to control (0.8 ± 0.08) or PGG alone (2.8 ± 0.08) (Figure 2) .
PGG influences the expression of cancer biomarkers and DAXX in K562 mouse xenograft model
To verify the in vivo anti-tumor efficacy of PGG, K562 cells were subcutaneously injected into Balb/c athymic nude mice in the flank area, and starting after 5 days inoculation, the mice were intraperitoneally administered PGG (4 or 10 mg/kg) or imatinib (25 or 50 mg/kg) (a positive control) every 2 days. Tumor growth was monitored for 18 days. As shown in Figure 3 , tumor size and weight in PGG-or imatinib-treated groups were decreased compared with untreated control without significant body weight loss. For analyzing biomarkers of anti-tumor efficiency, we conducted immunohistochemistry analysis with tumor sections from the mice (Figure  4) . The indicators of proliferation marker Ki-67 (first column) and vascular endothelial marker CD34 (second column) were significantly decreased in both PGG and imatinibtreated groups. Also, TUNEL positive stained cells were significantly increased in both PGG-and imatinibtreated mice (third column). Furthermore, positive cells for DAXX which are known as a proapoptotic protein were significantly reduced in PGG-and imatinib-treated mice (fourth column).
DISCUSSION
Several groups reported anti-cancer effects of natural products against CML through the reactive oxygen species (ROS) signaling. For instance, Mao et al. (2008) reported that shikonin induced apoptosis through the ROS/ c-Jun N-terminal kinases (JNK)-mediated process in CML cell lines K562 and LAMA84. Rakshit et al. (2010) reported the role of ROS in chlorogenic acid (Chi)-induced cell death in CML cell lines as well as primary leukemia cells from CML patients. In addition, Zhang et al. (2008) reported that beta-phenylethyl isothiocyanate (PEITC) exerted the cytotoxic effect in Glivec-resistant CML cells by regulating redox signaling. These evidences suggest the potential of natural products for CML treatment.
Combination cancer therapy has been thought as an effective process to increase the therapeutic efficiency of anti-cancer agents and reduce their adverse effects. Interestingly, PGG potentiated imatinib induced apoptosis as a combination therapy for CML with the value of CI > 1, determined by Chou-Talalay method and CalcuSyn software, implying significant synergism between PGG and imatinib. We recently found the protective effect of PGG on anti-cancer drug cisplatin-induced apoptosis in normal renal epithelial cells (data not shown), supporting the potential of PGG as a supplement of imatinib for a combination therapy for CML.
We finally found that PGG administration suppressed the growth of K562 xenograft without significant body weight loss. Immunohistochemistry showed decreased expression of Ki67 (proliferation), CD34 (angiogenesis), DAXX and increased TUNEL (apoptosis) positive cells in tumor sections of PGG treated mice, indicating the antitumor effects PGG were associated with antiproliferation, anti-angiogenesis and apoptosis induction.
PGG suppressed the growth of K562 cells in xenograft nude mice and also immunohistochemistry confirmed antitumor effects PGG were associated with antiproliferation, anti-angiogenesis and apoptosis induction. However, it still requires further study to confirm in vitro synergistic antitumor activity of PGG with imatinib in a large number of athymic nude mice and also elucidate molecular mechanism in another resistant CML cell lines in the near future.
Conclusion
PGG revealed the synergistic effect on imatinib-induced cell death in K562 cells in vitro and oral administration of PGG or imatinib significantly inhibited tumor size and weight of K562 cells inoculated in Balb/c athymic nude mice.
Furthermore, immunohistochemistry assay revealed that the expressions of proliferation marker Ki-67 and vascular endothelial marker CD34 and (DAXX) were inhibited and also apoptosis marker TUNEL stained cells were significantly increased from the tumor tissues from PGG or imanitib treated groups. Overall, our findings suggest that PGG showed anticancer potential to induce apoptosis and enhance antitumor activity of imatinib in K562 CML cells.
